RankAlpha logo
Back to Rankings

QGEN

QIAGEND
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
The constructive read is that QIAGEN preserved adjusted EPS delivery in Q1 2026 despite weaker CER sales, management framed QuantiFERON weakness as a 2026 rebasing rather than a long-term impairment, and Baird upgraded the shares to Buy/Outperform on April 29, 2026 while cutting its target to $43, suggesting some investors may view the selloff as valuation reset rather than franchise break.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +6.8.
What can break
QIAGEN's own forward-looking risk language flags product-development success, tariffs, currency, regulatory processes, customer funding variability, reimbursement/public-health funding and competition as ongoing risks to diagnostics and life-science growth [#6K-2026-04-27].
Momentum
43
Value
65
Sentiment
39
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $35.00 · Bull $39.00 · Bear $29.00Analysis 2026-05-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-09-09

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions

Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $45.83
Why
Momentum43 · Δ7d +9.1
Value65 · Δ7d -0.0
Sentiment39 · Δ7d +6.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.

Confirming evidence

  • • Sentiment remains the lead driver in the composite, 7D delta +6.8.

Contradictions & invalidation

  • • QIAGEN's own forward-looking risk language flags product-development success, tariffs, currency, regulatory processes, customer funding variability, reimbursement/public-health funding and competition as ongoing risks to diagnostics and life-science growth [#6K-2026-04-27].
  • • QuantiFERON sales declined 5% CER in Q1 2026, mainly due to a significant decline in immigration testing demand in the United States and Middle East, and management now expects 2026 QuantiFERON sales to be unchanged at CER versus 2025 sales of $503 million [#6K-2026-04-27].
  • • The bearish read is that the delayed post-print revision signal is still mixed-to-negative: JPMorgan reportedly cut its target to $45 from $60 while keeping Overweight, Citigroup cut to $38 from $55 while maintaining Hold, Barclays cut to $38 from $44 while maintaining Equal Weight, and the company itself cited lower immigration testing, cautious U.S.

Catalyst clock

2026-08-01

Post-earnings reset must stabilize after FY2026 cut [#6K-2026-04-27]

Lead driver: Sentiment · See AI snapshot
Momentum
43
9% active weight
Current posture
7d trendImproving
Δ7d
+9.1
Δ21d
-15.8
Value
65
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
39
62% active weight
Current posture
7d trendImproving
Δ7d
+6.8
Δ21d
+2.0
Why this grade

Composite grade D. Momentum 43.0 / Value 65.3 / Sentiment 39.5

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-08. Scenario method

B+
Bull case
25%
Probability
Target price
$39.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$35.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$29.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$8.78B
Beta
0.28
Shares Out
206.08M
P/E (TTM)
24.7
P/S (TTM)
4.77
P/FCF (TTM)
20.91
Rev YoY
+0.3%
EPS YoY
+7.1%
Gross Margin
+61.8%
Op Margin
+24.6%
Net Debt
$713.45M
Current Ratio
2.85
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data